Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: Al. Jana Pawła II 80, 00-175 Warszawa,Poland
Tel: +48 22 635-80-41
Web: http://www.lekam.pl/
LEK-AM Pharmaceutical Company Ltd., is a company that is expanding the most on the Polish
pharmaceutical market. LEK-AM combines a homogenous product portfolio, efficient leadership
and highly skilled employees, that allowed the company to quickly gain recognition in the
pharmaceutical industry.
Presently LEK-AM is one of the fastest growing pharmaceutical companies in Poland.
A rapid rate of growth in terms of sales and revenues, combined with a top quality of products
offered, has turned LEK-AM into a phenomenon of the market.
Year Product IMS ranking
2000 Company has been set up Position 350th
2001 Melatonina LEK-AM Position 165th
2002 Biosteron – DHEA Position 126th
2003 Maglek B6 Position 84th
2004 Ostolek Position 72nd
2005 Olzapin and Alerzina Position 58th
2006 Finaster and Risperon Position 48th
2007 Nobaxin Position 40th
2008 Diosminex, Clopidix i Corator
Introduction of dietary supplements
Position 36th
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here
